February 3, 2021 8:36 AM 27 seconds read

BioCryst Gains After FDA Nod For Expanded Use of RAPIVAB

by Vandana Singh Benzinga Editor
Follow
Comments
  • BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares jump after the FDA approved supplemental marketing application seeking approval for RAPIVAB (peramivir injection) to treat acute uncomplicated influenza to include patients six months and older who have been symptomatic for no more than two days.
  • Before this approval, RAPIVAB had been indicated for patients two years and older.
  • BCRX shares gained 7.03% at $11.27 pre-market on the last check Wednesday.
BCRX Logo
BCRXBioCryst Pharmaceuticals Inc
$6.826.40%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
84.51
Growth
82.31
Quality
-
Value
10.62
Price Trend
Short
Medium
Long
Overview
Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Posted In:
BiotechNewsSmall CapFDAGeneralinfluenza

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2025 Benzinga | All Rights Reserved